stockrowADMA Biologics Inc
ADMA Healthcare Biotechnology
ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024.
- Revenue
- +5.12%
- EPS
- +46.7%
- Free cash flow
- +1,709.5%
- Total debt
- +140.5%
Quarter to September 2026, against a year earlier
Follow ADMA
Alert me
ADMA Biologics Inc (ADMA) Revenue
ADMA Biologics Inc's revenue for fiscal 2025 was $510.2M, up 19.6% from $426.5M in fiscal 2024. Over the twelve months to 30 September 2026 it was $519.2M. Over the past ten years it has ranged from $7.2M (fiscal 2015) to $510.2M (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 7 consecutive fiscal years. ADMA Biologics Inc ranks 38th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $510.2M | 19.63% |
| FY2024 | $426.5M | 65.15% |
| FY2023 | $258.2M | 67.59% |
| FY2022 | $154.1M | 90.36% |
| FY2021 | $80.9M | 91.72% |
| FY2020 | $42.2M | 43.85% |
| FY2019 | $29.3M | 72.79% |
| FY2018 | $17.0M | (25.37%) |
| FY2017 | $22.8M | 113.49% |
| FY2016 | $10.7M | 48.53% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $141.1M | 13.43% |
| Jun 2026 | $124.4M | 8.65% |
| Mar 2026 | $114.5M | (17.73%) |
| Dec 2025 | $139.2M | 3.68% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| BHVN Biohaven Ltd. compare | $995.4M |
| ADMA ADMA Biologics Inc | $519.2M |
| VCEL Vericel Corporation compare | $324.2M |
| AUPH Aurinia Pharmaceuticals Inc compare | $321.7M |
| PVLA Palvella Therapeutics, Inc. compare | $41.6M |
| IMNM Immunome, Inc. compare | $12.6M |
| CLDX Celldex Therapeutics, Inc. compare | $887.0K |
| PHVS Pharvaris N.V. compare | — |
| VERA Vera Therapeutics, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on ADMA
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement